BUB
AXDX

BBVA USA Bancshares’s Accelerate Diagnostics AXDX Stock Holding History

BBVA USA Bancshares’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,083
Closed -$236K – 546
2014
Q1 		$236K Buy
+1,083
New +$160K 0.01% 497

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
SCM
Sandler Capital Management New York $201M AUM 84.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBVA USA Bancshares's AXDX Position: Q2 2014 in Review

BBVA USA Bancshares sold out of Accelerate Diagnostics (AXDX) in Q2 2014, closing a stake of 1,083 shares — an estimated $236K sold.

BBVA USA Bancshares first reported a position in AXDX in Q1 2014 and held it in 1 quarter. The position peaked at $236K in Q1 2014. 75 funds tracked by Wall St. Rank hold AXDX as of Q2 2014.

  • BBVA USA Bancshares reported no remaining Accelerate Diagnostics position as of Q2 2014 after selling out during the quarter.
  • BBVA USA Bancshares sold 1,083 Accelerate Diagnostics shares in Q2 2014, an estimated $236K.
  • BBVA USA Bancshares first reported a position in Accelerate Diagnostics in Q1 2014 and held it in 1 quarter.
  • BBVA USA Bancshares's Accelerate Diagnostics position peaked at $236K in Q1 2014.
  • 75 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2014.

Based on BBVA USA Bancshares's 13F filing for Q2 2014, filed 6 Aug 2014.